[Show abstract][Hide abstract] ABSTRACT: Evidence of harms associated with temazepam gel capsule injecting among injecting drug users in Australia led to its withdrawal from manufacture in Australia. Subsequently, diphenhydramine gel capsule injecting was identified among a subset of ethnic Vietnamese injecting drug users.
Observational fieldwork around an active street-based illicit drug marketplace together with targeted purposive sampling enabled 66 ethnic Vietnamese injecting drug users to be recruited for in-depth interview.
Data revealed that the injection of gel capsules increases exposure to non-viral infections. Analysis of participant interviews show how participants have established their own ways of reducing these harms including thinning the drug solution by jacking regularly during injection. Controversially, femoral vein administration of diphenhydramine-heroin cocktails was also seen as a harm reduction strategy by participants.
Health education campaigns to address the potentially negative consequences of gel capsule groin injection will not be successful unless health workers and policy makers work with drug users and incorporate local understandings and meanings of risk in health promotion activities.
The International journal on drug policy 10/2008; 20(4):340-6. · 2.54 Impact Factor
[Show abstract][Hide abstract] ABSTRACT: The hepatitis C virus (HCV) affects over 170 million people worldwide. In Australia, over 225,000 people have been diagnosed with HCV infection with 13,000 infections reported annually; 90% are attributed to injecting drug use. Burnet Institute (BI) researchers have been studying the HCV epidemic since the virus was identified in 1989 including community based cohort studies (1990-1995), numerous studies involving Vietnamese-Australian people who inject drugs (PWID) (1996-2004) and social network studies (2000-2002, 2005-2007). Through this work the BI has developed a model of research practice for HCV and PWID, developed in recognition that much research relating to BBV infections - and HCV in particular - could be improved in terms of provision of test results to study participants. Our model endeavours to provide all participants with the highest quality HCV test results, delivered in accordance with best practice for pre- and post-test counselling by engaging participants in environments in which they are comfortable, building trust and rapport and being available throughout and beyond the research study. This paper will discuss the benefits and lessons learned over numerous studies in providing pre- and post-test counselling to PWID in an outreach capacity.
The International journal on drug policy 03/2008; 19(1):66-70. · 2.54 Impact Factor